OOIR: Observatory of International Research

Papers

(The TQCC of American Journal of Clinical Dermatology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative	238
The Current State of Systemic Therapy of Metastatic Uveal Melanoma	173
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	118
Prognostic Biomarkers in Evolving Melanoma Immunotherapy	101
Economic Burden of Chronic Hand Eczema: A Review	99
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions	93
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	91
The Burden of Pediatric Psoriasis: A Systematic Review	91
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review	91
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials	84
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma	72
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know	66
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study	66
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments	65
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution	64
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data	61
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks	61
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi	61
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?	61
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review	61
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology	57
Pathophysiology of Generalized Pustular Psoriasis	56
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	55
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation	54
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study	53

Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”	52
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment	48
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry	47
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature	47
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials	46
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission	45
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review	45
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis	45
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management	44
A Practice Approach to Acne Fulminans in Adolescents	43
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis	42
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives	41
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment Hist	41
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment	41
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa	40
Patient and Public Involvement in Dermatology Research: A Review	40
Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm	40
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases	39
A Review of the Etiologies and Key Clinical Features of Secondary Hyperhidrosis	38
Scratching the Surface: A Comprehensive Guide to Understanding and Managing Vulvovaginal Itching	37
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review	36
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates	36
Oral Lichen Planus: An Update on Diagnosis and Management	35
Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”	35
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada	34
Frontal Fibrosing Alopecia: An Update	33
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists	31
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History	31
Individualized Neoantigen-Directed Melanoma Therapy	31
The Burden of Acne Vulgaris on Health-Related Quality of Life and Psychosocial Well-Being Domains: A Systematic Review	31
JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential	30
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials	28
Advancing Precision Medicine in Inflammatory Skin Disease	28
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study	28
Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”	27
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)	27
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program	27
Targeting Inflammation in Acne: Current Treatments and Future Prospects	27
Management of Acne in Pregnancy	26
Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis	26
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results	26
Acknowledgement to Referees	26
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	26
Cutaneous Small Vessel Vasculitis: A Practical Guide to Diagnosis and Management	25
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study	25
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year	25
Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review	24
Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study	24
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients	24
Exploring Suzetrigine's Role in Dermatologic Surgery: A Novel Nonopioid Analgesic for Postoperative Pain Management	24

Approach to the Atypical Wound	24
Is There a Place for Biologics in Acne?	23
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey	23
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea	23
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials	22
Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)	22
Safety of Hydroxychloroquine: What a Dermatologist Should Know	21
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study	21
The 25th World Congress of Dermatology, Singapore, 3–8 July, 2023: Research Highlights	21
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations	21
Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study	20